Company / Cash & Equivalents
ClearPoint Neuro, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$45.9M
FY2025
5-year range
$20.1M / $54.1M
FY2021-FY2025
Trend
+128.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $46M.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +18.0%.
Improved from $23M to $46M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +18.5%
- 5-Year CAGR
- +18.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +18.0%, indicating consistent growth.
- In FY2025, cash & equivalents increased 128.4% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.71 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.9M | +128.4% |
| FY2024 | $20.1M | -13.1% |
| FY2023 | $23.1M | -16.2% |
| FY2022 | $27.6M | -49.0% |
| FY2021 | $54.1M | +169.2% |
| FY2020 | $20.1M | +252.9% |
| FY2019 | $5.7M | +83.7% |
| FY2018 | $3.1M | -66.6% |
| FY2017 | $9.3M | +180.2% |
| FY2016 | $3.3M | -38.7% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026